VC-backed OptiNose debuts IPO
Yardley, Pennsylvania-based OptiNose, a developer of ear, nose, throat and allergy products, has raised $120 million for its IPO after pricing its 7.5 million shares at $16 per share. The stock began trading October 13, 2017 on the NASDAQ under the ticker symbol "OPTN." Jefferies and Piper Jaffray are the lead underwriters. OptiNose's backers include Avista Capital Partners, WFD Ventures and Entrepreneurs Fund.
13 October 2017•3 mins read
